[go: up one dir, main page]

PL2150561T3 - Pozbawiony mannozy zrekombinowany czynnik VIII do leczenia pacjentów z hemofilią A - Google Patents

Pozbawiony mannozy zrekombinowany czynnik VIII do leczenia pacjentów z hemofilią A

Info

Publication number
PL2150561T3
PL2150561T3 PL08762760T PL08762760T PL2150561T3 PL 2150561 T3 PL2150561 T3 PL 2150561T3 PL 08762760 T PL08762760 T PL 08762760T PL 08762760 T PL08762760 T PL 08762760T PL 2150561 T3 PL2150561 T3 PL 2150561T3
Authority
PL
Poland
Prior art keywords
demannosylated
haemophilia
patients
treatment
factor viii
Prior art date
Application number
PL08762760T
Other languages
English (en)
Inventor
Abdessatar Sami Chtourou
DESMAZES Sébastien LACROIX
Srinivas Kaveri
Suryasarathi Dasgupta
Jagaadeesh Bayry
Original Assignee
Lfb Biotechnologies
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lfb Biotechnologies, Inst Nat Sante Rech Med filed Critical Lfb Biotechnologies
Publication of PL2150561T3 publication Critical patent/PL2150561T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08762760T 2007-04-20 2008-04-21 Pozbawiony mannozy zrekombinowany czynnik VIII do leczenia pacjentów z hemofilią A PL2150561T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290495A EP1985631A1 (en) 2007-04-20 2007-04-20 Demannosylated recombinant factor VIII for the treatment of patients with hemophiila A
PCT/IB2008/001417 WO2008129422A1 (en) 2007-04-20 2008-04-21 Demannosylated recombinant factor vii for the treatment of patients with haemophilia a
EP08762760A EP2150561B1 (en) 2007-04-20 2008-04-21 Demannosylated recombinant factor VIII for the treatment of patients with haemophilia A

Publications (1)

Publication Number Publication Date
PL2150561T3 true PL2150561T3 (pl) 2012-03-30

Family

ID=38515425

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08762760T PL2150561T3 (pl) 2007-04-20 2008-04-21 Pozbawiony mannozy zrekombinowany czynnik VIII do leczenia pacjentów z hemofilią A

Country Status (15)

Country Link
US (1) US8802620B2 (pl)
EP (2) EP1985631A1 (pl)
JP (1) JP2010524453A (pl)
KR (1) KR20100017142A (pl)
CN (1) CN101970481A (pl)
AR (1) AR066132A1 (pl)
AT (1) ATE530575T1 (pl)
AU (1) AU2008240663A1 (pl)
BR (1) BRPI0810592A2 (pl)
CA (1) CA2684834A1 (pl)
DK (1) DK2150561T3 (pl)
ES (1) ES2376022T3 (pl)
PL (1) PL2150561T3 (pl)
TW (1) TW200914608A (pl)
WO (1) WO2008129422A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102137935A (zh) * 2008-06-25 2011-07-27 拜耳医药保健有限公司 具有降低的免疫原性的因子viii突变蛋白
FR2933496B1 (fr) * 2008-07-02 2012-10-05 Lfb Biotechnologies Procede de mesure du taux de facteur vii active dans un echantillon
WO2014198699A2 (en) * 2013-06-12 2014-12-18 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
MX2016005333A (es) 2013-10-22 2017-02-15 Dbv Tech Método para tratar la hemofilia induciendo tolerancia a factores sanguíneos.
EP3114138B1 (en) 2014-03-05 2021-11-17 Pfizer Inc. Improved muteins of clotting factor viii
EP3253786A4 (en) * 2015-02-06 2018-10-17 The University of North Carolina at Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
AU2016343887B2 (en) * 2015-10-28 2023-04-06 Sangamo Therapeutics, Inc. Liver-specific constructs, factor VIII expression cassettes and methods of use thereof
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
US11306329B2 (en) * 2018-02-19 2022-04-19 City Of Hope Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof
CN112575034B (zh) * 2019-09-29 2023-04-25 济南赛尔生物科技股份有限公司 一种治疗a型血友病的产品及应用
CN113248594B (zh) * 2021-04-26 2022-08-30 北京美康基免生物科技有限公司 一种重组凝血因子viii及其应用
CN116710554B (zh) * 2021-11-25 2024-06-07 四川至善唯新生物科技有限公司 基因工程改造获得的分泌能力和凝血活性增强的人类八因子

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DE59914490D1 (de) * 1998-11-10 2007-10-18 Sanquin Bloedvoorziening Ein faktor viii-polypeptid mit faktor viii:c-aktivität
WO2002096454A1 (en) * 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
EP1682106A4 (en) * 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods

Also Published As

Publication number Publication date
KR20100017142A (ko) 2010-02-16
CN101970481A (zh) 2011-02-09
BRPI0810592A2 (pt) 2014-10-21
EP1985631A1 (en) 2008-10-29
EP2150561A1 (en) 2010-02-10
JP2010524453A (ja) 2010-07-22
WO2008129422A8 (en) 2009-11-19
AR066132A1 (es) 2009-07-22
DK2150561T3 (da) 2011-12-19
TW200914608A (en) 2009-04-01
AU2008240663A1 (en) 2008-10-30
US8802620B2 (en) 2014-08-12
ATE530575T1 (de) 2011-11-15
ES2376022T3 (es) 2012-03-08
CA2684834A1 (en) 2008-10-30
EP2150561B1 (en) 2011-10-26
US20100197578A1 (en) 2010-08-05
WO2008129422A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
PL2150561T3 (pl) Pozbawiony mannozy zrekombinowany czynnik VIII do leczenia pacjentów z hemofilią A
IL200163A0 (en) Therapeutic hybrid implantable devices
ZA201000013B (en) Medical implant
ZA201001417B (en) Medical implant
IL246189B (en) Medicine in dry powder form
GB0602178D0 (en) Therapeutic treatment
PL3338791T3 (pl) Terapeutyczne dawkowanie neureguliny do leczenia lub zapobiegania niewydolności serca
PL2247297T3 (pl) Działanie terapeutyczne w stanach chorobowych płuc
GB2465925B (en) Track for patient lift devices
IL196667A (en) Use of peptides to prepare a drug to treat inflammation
ZA201003362B (en) Interfaced medical implant assembly
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
IL200032A0 (en) Medicament for the treatment of endometriosis
GB0608655D0 (en) Therapeutic Treatment
GB0710981D0 (en) New Therapeutic use
EP2269665A4 (en) VISIBLE MEDICAL TREATMENT MATERIAL
GB0610909D0 (en) Therapeutic treatment
GB0704334D0 (en) Patient bed
EP2254901A4 (en) THERAPEUTIC PEPTIDES
GB0724517D0 (en) Patient extremity drape
GB0717450D0 (en) Medicament
ZA200905300B (en) Medicament for the treatment of endometriosis
GB0808690D0 (en) Therapeutic use
ZA200809086B (en) Patient care
GB0610376D0 (en) Therapeutic treatment